Abstract
In the course of our ongoing program dedicated to the synthesis of anti-proliferative compounds, we prepared new troglitazone derivatives bearing a biphenyle moiety. The chromane heterocycle was further replaced by imidazole and triazole derivatives. Many compounds exhibited fair to high activity towards various cancer cell lines. Among them, compound 17b reduced cell viability leading to only 22-34% viable cells in four cancer cell lines at 10 µM, but unfortunately also led to a low (13%) cell viability of non-malignant primary cultured human hepatocytes at 200 µM. Interestingly, compound 11b also reduced cell viability in colon and liver cancer cell lines (29% and 24% cell viability respectively at 10 µM), but maintained a high cell viability of non-malignant hepatocytes (reaching 71% cell viability at 200 µM), thus exhibiting a huge selectivity.
Keywords: Cancer, Chromane, Hepatotoxicity, Imidazole, Thiazolidine-2, 4-dione, Triazole, Troglitazone.
Letters in Drug Design & Discovery
Title:Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores
Volume: 11 Issue: 3
Author(s): Maxime Meyer, Sandra Kuntz, Isabelle Grillier-Vuissoz, Helene Martin, Lysiane Richert, Stephane Flament, Yves Chapleur and Michel Boisbrun
Affiliation:
Keywords: Cancer, Chromane, Hepatotoxicity, Imidazole, Thiazolidine-2, 4-dione, Triazole, Troglitazone.
Abstract: In the course of our ongoing program dedicated to the synthesis of anti-proliferative compounds, we prepared new troglitazone derivatives bearing a biphenyle moiety. The chromane heterocycle was further replaced by imidazole and triazole derivatives. Many compounds exhibited fair to high activity towards various cancer cell lines. Among them, compound 17b reduced cell viability leading to only 22-34% viable cells in four cancer cell lines at 10 µM, but unfortunately also led to a low (13%) cell viability of non-malignant primary cultured human hepatocytes at 200 µM. Interestingly, compound 11b also reduced cell viability in colon and liver cancer cell lines (29% and 24% cell viability respectively at 10 µM), but maintained a high cell viability of non-malignant hepatocytes (reaching 71% cell viability at 200 µM), thus exhibiting a huge selectivity.
Export Options
About this article
Cite this article as:
Meyer Maxime, Kuntz Sandra, Grillier-Vuissoz Isabelle, Martin Helene, Richert Lysiane, Flament Stephane, Chapleur Yves and Boisbrun Michel, Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/15701808113106660080
DOI https://dx.doi.org/10.2174/15701808113106660080 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Anti-cancer Effects of Curcumin on Head and Neck Cancers
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: Current Status and Therapeutic Implications in Cancer Therapy-A New Paradigm
Current Stem Cell Research & Therapy Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Current Cancer Drug Targets Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Role of IRF1 and IRF2 Transcription Factors in Leukaemogenesis
Current Gene Therapy Higher Placental Anti-Inflammatory IL-10 Cytokine Expression in HIV-1 Infected Women Receiving Longer Zidovudine Prophylaxis Associated with Nevirapine
Current HIV Research Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry